← Leaderboards
Jeffrey Robert Strawn
University Of Cincinnati
$6,370,690
Attributed
$11,345,011
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.5M · FY2014–25$10M$7.5M$5M$2.5M$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$24,905,467 · 5
By mechanism
UL1$13,560,456 · 1
R01$5,300,738 · 2
UM1$5,299,021 · 1
K23$745,252 · 1
Top collaborators
- Laura B Ramsey6 shared
- Jareen Meinzen-Derr4 shared
- Achala Sameer Vagal4 shared
- Jessica A Kahn2 shared
Most similar at University Of Cincinnati
Same institution · by research overlap
- Susan Mengel Pinney$10,676,998
- Achala Sameer Vagal$6,346,822
- Brett M Kissela$26,412,165
- George Douglas Leikauf$18,622,175
Others in their field
Top investigators on “Child”
- Barbara Driver · Westat, Inc.$244,454,458
- Sharon A Nachman · Johns Hopkins University$212,395,175
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$195,214,889
- George R Seage · Abt Associates, Inc.$189,009,744
- Carol Nesel · Westat$188,148,170
- Elizabeth A Thom · George Washington University$170,579,744
Research focus
ChildSuccessChildhoodSelective Serotonin Reuptake InhibitorTreatment ResponseAnxiety DisordersAdolescentAffectYouthEscitalopramPsychopharmacologicAdultChildhood AnxietyPediatric PatientsResponseAntidepressive AgentsBaseSafetyRandomizedImpairmentPsychosocialRandomized TrialAgitationDose
Grant awards (19)
Center for Clinical and Translational Science and Training$5,299,021
UM1 · FY2025 · TR
Center for Clinical and Translational Science and Training$4,520,152
UL1 · FY2024 · TR
Improving the Effectiveness and Safety of Escitalopram in Pediatric Anxiety$556,564
R01 · FY2024 · HD · contact PI
Estracellular Vesicles as Non-Invasive Predictors of Antidepressant Outcomes in Pediatric Anxiety$454,389
R01 · FY2024 · HD · contact PI
Center for Clinical and Translational Science and Training$4,520,152
UL1 · FY2023 · TR
Improving the Effectiveness and Safety of Escitalopram in Pediatric Anxiety$424,833
R01 · FY2023 · HD · contact PI
Improving the Effectiveness and Safety of Escitalopram in Pediatric Anxiety Disorders Using Pharmacogenetically-guided Dosing$124,767
R01 · FY2023 · HD
Center for Clinical and Translational Science and Training$4,520,152
UL1 · FY2022 · TR
Improving the Effectiveness and Safety of Escitalopram in Pediatric Anxiety Disorders Using Pharmacogenetically-guided Dosing$549,601
R01 · FY2022 · HD
Estracellular Vesicles as Non-Invasive Predictors of Antidepressant Outcomes in Pediatric Anxiety$471,436
R01 · FY2022 · HD · contact PI
Improving the Effectiveness and Safety of Escitalopram in Pediatric Anxiety Disorders Using Pharmacogenetically-guided Dosing$546,930
R01 · FY2021 · HD
Estracellular Vesicles as Non-Invasive Predictors of Antidepressant Outcomes in Pediatric Anxiety$473,506
R01 · FY2021 · HD · contact PI
Improving the Effectiveness and Safety of Escitalopram in Pediatric Anxiety Disorders Using Pharmacogenetically-guided Dosing$680,585
R01 · FY2020 · HD
Estracellular Vesicles as Non-Invasive Predictors of Antidepressant Outcomes in Pediatric Anxiety$487,628
R01 · FY2020 · HD · contact PI
Estracellular Vesicles as Non-Invasive Predictors of Antidepressant Outcomes in Pediatric Anxiety$530,499
R01 · FY2019 · HD · contact PI
Neurofunctional Predictors of Treatment Response in Adolescents with GAD$186,313
K23 · FY2017 · MH · contact PI
Neurofunctional Predictors of Treatment Response in Adolescents with GAD$186,313
K23 · FY2016 · MH · contact PI
Neurofunctional Predictors of Treatment Response in Adolescents with GAD$186,313
K23 · FY2015 · MH · contact PI
Neurofunctional Predictors of Treatment Response in Adolescents with GAD$186,313
K23 · FY2014 · MH · contact PI